Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer.
Hirokazu TaniguchiHiroyuki YamaguchiYosuke DotsuMidori ShimadaHiroshi GyotokuHiroaki SenjuShinnosuke TakemotoTakeshi KitazakiMasaaki FukudaDaiki OgawaraHiroshi SodaKatsumi NakatomiNanae SugasakiAkitoshi KinoshitaSeiji NagashimaTakaya IkedaYoichi NakamuraNoriho SakamotoYasushi ObaseMinoru FukudaHiroshi MukaePublished in: Thoracic cancer (2019)
The efficacy of the combination of nedaplatin and amrubicin was comparable to that of other conventional chemotherapeutic regimens for treatment-naïve patients with advanced SCC, and no severe gastrointestinal or neuromuscular toxicities were observed. This combination therapy may be an alternative treatment approach, particularly in patients who cannot tolerate gastrointestinal or neuromuscular toxicities.